Leerink analyst Mike Kratky initiated coverage of Boston Scientific (BSX) with an Outperform rating and $118 price target The firm notes Boston Scientific’s top-tier, double digit topline and EPS growth profile and impressive track record of commercial execution have helped make it one of the most well-regarded companies in the MedTech space. The stock has also been a juggernaut over the past decade and seemingly remains a consensus long, Leerink adds. Despite already lofty expectations, the firm’s deep-dive analysis on the atrial fibrillation market points to FARAPULSE and WATCHMAN likely driving further upside for the company. Additionally, Boston Scientific’s commitment to investing in innovation through accretive M&A over the past few years should help support its durable above-market growth on a longer-term basis, in Leerink’s view.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strong Market Position and Innovative Pipeline Drive Buy Rating
- Boston Scientific’s Growth Potential Remains Strong Despite Product Discontinuation
- Boston Scientific Acurate TAVR discontinuation a positive, says Barclays
- Boston Scientific news ‘zero surprise,’ says JPMorgan
- Citi sees Boston Scientific stopping TAVR valve sales as ‘wise move’